Table 1.
Estimated number of new cancer diagnoses and weights* by 5-year age group for the three standards of the world cancer patient population (WCPP). Source: GLOBOCAN 2018.
| Standard 1a | Standard 2b | Standard 3c | ||||
|---|---|---|---|---|---|---|
| Age | Number of patients | Weight | Number of patients | Weight | Number of patients | Weight |
| 0−4 | 2654 | 1.32 | 12,648 | 0.15 | 62,882 | 1.10 |
| 5−9 | 3559 | 1.62 | 5434 | 0.07 | 50,019 | 0.97 |
| 10−14 | 6581 | 3.23 | 4169 | 0.05 | 43,054 | 0.96 |
| 15−19 | 12,129 | 6.11 | 8135 | 0.10 | 41,995 | 1.18 |
| 20−24 | 17,209 | 8.91 | 20,159 | 0.25 | 56,109 | 1.57 |
| 25−29 | 21,498 | 11.31 | 38,414 | 0.52 | 115,340 | 2.73 |
| 30−34 | 22,760 | 12.12 | 71,576 | 1.01 | 199,583 | 4.21 |
| 35−39 | 20,750 | 11.16 | 124,836 | 1.67 | 278,586 | 5.44 |
| 40−44 | 17,160 | 9.22 | 247,155 | 3.05 | 376,464 | 7.18 |
| 45−49 | 13,752 | 7.30 | 488,333 | 5.26 | 490,219 | 9.35 |
| 50−54 | 10,971 | 5.68 | 818,074 | 8.05 | 567,795 | 10.69 |
| 55−59 | 9306 | 4.71 | 1,189,485 | 10.91 | 595,446 | 11.21 |
| 60−64 | 8369 | 4.16 | 1,562,213 | 13.46 | 591,639 | 11.18 |
| 65−69 | 7553 | 3.75 | 1,831,412 | 14.78 | 545,112 | 10.23 |
| 70−74 | 6143 | 3.09 | 1,664,726 | 13.18 | 425,206 | 7.84 |
| 75−79 | 4919 | 2.53 | 1,380,864 | 10.93 | 320,646 | 5.91 |
| 80−84 | 3696 | 1.95 | 1,087,515 | 8.57 | 233,944 | 4.32 |
| 85+ | 3377 | 1.83 | 1,008,407 | 7.99 | 212,576 | 3.93 |
| Total | 192,386 | 100 | 11,563,555 | 100 | 5,206,615 | 100 |
The numbers of patients reflect the number of cancer cases included in each standard. Weights represent the mixture of proportion of new cancer cases across age groups and cancer types.”.
Standard 1: Hodgkin lymphoma (C81), Kaposi sarcoma (C46), and testis (C62).
Standard 2: Anus (C21), bladder (C67), colon (C18), corpus uteri (C54), gallbladder (C23‐C24, incl. extrahepatic ducts), hypopharynx (C12‐C13), kidney (C64‐C65, incl. renal pelvis), larynx (C32), liver (C22, including intrahepatic bile ducts), lung (C33‐C34, incl. trachea and bronchus), melanoma of the skin (C43), non-melanoma skin cancer (C44), mesothelioma (C45), multiple myeloma (C88 and C90, incl. immunoproliferative diseases), oesophagus (C15), oropharynx (C09‐C10), pancreas (C25), penis (C60), prostate (C61), rectum (C19−20), stomach (C16), vagina (C52), and vulva (C51).
Standard 3: Brain, central nervous system (C70‐C72), breast (C50), cervix uteri (C53), leukemia (C91‐C95), lip, oral cavity (C00‐C06), nasopharynx (C11), thyroid (C73), non‐Hodgkin lymphoma (C82‐C86 and C96), ovary (C56), and salivary glands (C07‐C08).